Photographer captures ghostly ripples over Colorado night sky 'it is rare to see it directly overhead and moving like that' (photo)

When you buy through links on our articles, Future and its syndication partners may earn a commission.
Beneath the star-drenched skies of Colorado on May 26, as the Milky Way arched into view, photographer Aaron Watson pointed his lens upward — and captured something extraordinary unfolding in the night.
"I have seen airglow a lot, but it is rare to see it directly overhead and moving like that," Watson told Space.com in an email.
Watson's timelapse, captured around 3:30 a.m. local time and spanning about 30 minutes, reveals watery green ripples of airglow sweeping across the sky. "It was, for the most part, invisible to the naked eye," Watson said.
Airglow is a natural light emission created when sunlight interacts with molecules in Earth's upper atmosphere, causing them to release energy as a faint glow. There are three types of airglow: dayglow, twilightglow and nightglow, according to Lancaster University's Aurora Watch UK.
Dayglow and twilightglow are driven by the same process — sunlight charging atmospheric molecules — but twilight glow becomes briefly visible to the naked eye as daylight fades. These glowing emissions are about a billion times fainter than sunlight, which is why they're washed out during the day.
Watson captured nightglow, the most visible type of airglow, created by a process called chemiluminescence. During the day, sunlight deposits energy into our atmosphere, charging up oxygen molecules (O₂) high above Earth. Around 62 miles (100 kilometers) up, some of the energy splits these molecules into individual oxygen atoms. These atoms hang onto that sun-deposited energy for hours because they can't easily release it. Eventually, the oxygen atoms find partners and recombine to form O₂ again. When they do, they release the stored energy as light, including that striking green glow captured in Watson's timelapse.
The mesmerizing wave-like patterns seen in Watson's timelapse are the result of nearby thunderstorms producing gravity waves in the upper atmosphere. These waves ripple through the airglow, creating visible, wavelike patterns across the night sky.
RELATED STORIES
—Not 'Little Red Dots' or roaring quasars: James Webb telescope uncovers new kind of 'hidden' black hole never seen before
—Hold the syrup: Weirdly perfect 'pancakes' on Venus may prove the planet is buckling
—World's first color images of black holes are on their way
"North is down in this image set, so the ripples were flowing from south to north, as if flowing out from above the storms to the south." Watson wrote in a post on his website.
You can see more of Watson's impressive photography on his website Skies Alive. If this article has inspired you to get into astrophotography, our best cameras for astrophotography and best lenses for astrophotography can help you get ready to capture the next stunning skywatching event.
This article was originally published on Space.com.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

CBS News

6 minutes ago

• CBS News

Hermit Woods Winery in New Hampshire takes different approach to winemaking

An innovative craft winery located in downtown Meredith, New Hampshire, Hermit Woods is taking a different approach to winemaking. Host Rachel Holt learns all about why they are so dedicated to overturning tradition, and how their non-conventional process sets them apart. Rachel Holt Rachel Holt is a lifestyle reporter for WBZ-TV.

Medscape

21 minutes ago

• Medscape

Once-Weekly Efsitora Noninferior to Daily Insulin in T2D

CHICAGO — The investigational once-weekly basal insulin analog efsitora alfa lowered A1c as effectively as daily basal insulins in people with type 2 diabetes (T2D) who require insulin, showed three trials from the QWINT global phase 3 clinical trial program. However, two of the trials showed increased mild hypoglycemia in patients treated with efsitora, which some experts say is a concern. The QWINT-1 trial compared the efficacy and safety of a fixed-dose regimen of efsitora with once-daily glargine for 52 weeks in insulin-naive people with T2D; QWINT-3 compared efsitora with daily degludec for 78 weeks in adults already taking basal insulin; and QWINT-4 compared efsitora with daily glargine for 26 weeks in adults with T2D taking both basal and pre-meal bolus insulin. Results from the three trials were presented on June 22 during a single symposium here at the American Diabetes Association (ADA) 85th Scientific Sessions and simultaneously published in the New England Journal of Medicine (QWINT-1) and The Lancet (QWINT-3 and QWINT-4). QWINT-1: Fixed-Dose Efsitora QWINT-1 was an open-label trial of 795 adults with T2D who had not previously taken insulin. Participants were randomized to weekly efsitora delivered by a single-use auto-injector or daily injected insulin glargine. Efsitora was titrated to four fixed doses at 4-week intervals, as needed for blood glucose control. At week 52, efsitora had reduced A1c from 8.20% at baseline to 7.05% (–1.19 percentage points), compared with 8.28% to 7.08% with glargine (–1.16 percentage points), confirming noninferiority. "The novel fixed-dose regimen used in QWINT-1 for once-weekly efsitora, with titration options of only four different doses, can facilitate and substantially simplify initiating and escalating insulin therapy, potentially changing the insulin management paradigm in type 2 diabetes," lead investigator Julio Rosenstock, MD, senior scientific advisor for Velocity Clinical Research and clinical professor of medicine at the University of Texas Southwestern Medical Center, Dallas, said during a press briefing held at the meeting. In addition, the rate of combined clinically significant hypoglycemia (< 54 mg/dL) or severe hypoglycemia (requiring assistance for treatment) was significantly lower with efsitora than glargine (0.50 vs 0.88 events per participant-year of exposure with glargine [estimated rate ratio, 0.57]). In an editorial accompanying QWINT-1, NEJM Deputy Editor Julie R. Ingelfinger, MD, and Clifford J. Rosen, MD, director of clinical and translational research and a senior scientist at Maine Medical Center's Research Institute, Scarborough, write: "The present trial of efsitora potentially offers a ready-made and possibly straightforward algorithm for dose escalation. If packaged at a widely affordable price, efsitora would most likely simplify glycemic control for many persons with type 2 diabetes." However, limitations of QWINT-1 include the open-label design and lack of use of continuous glucose monitoring (CGM), Ingelfinger and Rosen note. QWINT-3 and QWINT-4 In both QWINT-3 and QWINT-4, efsitora was administered using traditional insulin dosing with adjustments based on each patient's glucose level. In QWINT-3, 986 adults with T2D who had already been treated with basal insulin and other noninsulin glucose-lowering medications, were randomized 2:1 to weekly efsitora or daily degludec. At week 26, A1c decreased by 0.81 percentage points with efsitora versus 0.72 with degludec, also meeting the noninferiority margin. Combined level 2 and 3 hypoglycemia from baseline to week 78 was similar in the efsitora and degludec groups, at 0.84 versus 0.74 events per patient-year, respectively. However, level 1 (mild) hypoglycemia was significantly more common with efsitora (8.34 vs 6.05; P = .0005). Nine deaths occurred during the trial but none were related to study treatment. In QWINT-4, 730 participants with T2D who had been treated with both basal and prandial insulin and up to three noninsulin glucose-lowering agents were randomized to efsitora or glargine U100, both with premeal insulin lispro. Mean baseline A1c was 8.18%. At 26 weeks, mean A1c was 7.17% in the efsitora group and 7.18% in the glargine group, meeting noninferiority criteria. As in QWINT-3, rates of moderate/severe hypoglycemia in QWINT-4 did not differ between the efsitora and glargine groups (6.6 vs 5.9 events per patient-year; P = .44), but mild hypoglycemia was more common with efsitora (25.3 vs 19.0; P < .0004). Other adverse event rates were similar. Is Hypoglycemia a Problem With Weekly Insulin? These three new studies round out the QWINT program, as results from QWINT-5, in type 1 diabetes (T1D), and from QWINT-2, in insulin-naive adults with T2D, were presented at the European Association for the Study of Diabetes (EASD) 2024 Annual Meeting. Hypoglycemia emerged as a significant issue with efsitora compared with insulin degludec in adults with T1D in the QWINT-5 trial. Another once-weekly insulin analog, Novo-Nordisk's insulin Icodec, has been approved under the brand name Awiqli in the European Union, Canada, Australia, Japan, and Switzerland for T1D and T2D, and in China for T2D. However, the US Food and Drug Administration requested more data to address the concern about hypoglycemia in T1D. "The risk of hypoglycemia remains a crucial factor when evaluating the safety of novel insulin preparations with a long half-life, such as efsitora, which has a half-life of 17 days," wrote Edith WK Chow, MD, and Elaine Chow, MD, PhD, both of The Chinese University of Hong Kong, in an editorial accompanying QWINT-3 and QWINT-4. "In both trials, the efsitora group had higher rates of overall level 1 hypoglycemia. When stratified by study timeline, higher rates of hypoglycemia were observed within the first 12 weeks of the study in both trials," they point out. In addition, they note that because CGM use was only intermittent and masked for participants, "the actual rate of hypoglycemic events might be underestimated, especially in the presence of hypoglycemia unawareness, which has been reported to be as high as 40% of people with type 2 diabetes using continuous glucose monitoring. Even asymptomatic episodes might be associated with increased cardiovascular risk." Asked about this at the press briefing, Rosenstock said that the increased mild hypoglycemia was "just little numerical imbalances. And the most important thing is that the number of events per patient per year are very low. It's less than one event per patient per year. I think that is something that we can take." Asked to comment on all three new QWINT studies, independent industry consultant Charles Alexander, MD, told Medscape Medical News : "Whether once-weekly insulin will be an advantage compared to once-daily insulin will depend upon factors like cost, convenience, and individual preference." Ingelfinger and Rosen agree with Alexander that the use of efsitora may depend on coverage, cost, and availability. "Long-term, formal government approval for efsitora is awaited, and uptake by patients is not yet known," they write. "The advent of newer or more effective noninsulin hypoglycemic drugs such as the GLP-1 receptor agonists, which simultaneously also produce weight loss, might ultimately be a more appealing option than efsitora and allow greater patient adherence than weekly insulin in some patients with type 2 diabetes." Despite these unknowns and caveats, the development of even longer-acting insulins now offers promising options for better glucose control in this disease," Ingelfinger and Rosen conclude. Rosenstock has reported receiving research grant support from, serving on advisory boards for, and/or receiving consulting fees honoraria from Applied Therapeutics, AstraZeneca, Biomea Fusion, Boehringer Ingelheim, Corcept, Eli Lilly, Hanmi, Merck, Novartis, Novo Nordisk, Oramed, Pfizer, Regeneron, Regor Therapeutics, Roche, Sanofi, Structure Therapeutics, and Terns Pharmaceuticals. Ingelfinger is a licensee of St. Martin's Press. Edith WK Chow has reported receiving travel sponsorship from Boehringer Ingelheim. Elaine Chow has reported receiving speaker honoraria from AstraZeneca, Boehringer Ingelheim, and Sinocare and institutional research grant support from Hua Medicine, Merck KGaA, and Medtronic Diabetes. All proceeds were donated to The Chinese University of Hong Kong for research purposes. Rosen and Alexander had no disclosures.

Forbes

31 minutes ago

• Forbes

NYT ‘Strands' Hints, Spangram And Answers For Monday, June 23

Strands Looking for Sunday's Strands hints, spangram and answers? You can find them here: How To Play Strands The New York Times' Strands puzzle is a play on the classic word search. It's in beta for now, which means it'll only stick around if enough people play it every day. There's a new game of Strands to play every day. The game will present you with a six by eight grid of letters. The aim is to find a group of words that have something in common, and you'll get a clue as to what that theme is. When you find a theme word, it will remain highlighted in blue. You'll also need to find a special word called a spangram. This tells you what the words have in common. The spangram links two opposite sides of the board. While the theme words will not be a proper name, the spangram can be a proper name. When you find the spangram, it will remain highlighted in yellow. Be warned: You'll need to be on your toes. 'Some themes are fill-in-the-blank phrases. They may also be steps in a process, items that all belong to the same category, synonyms or homophones,' The New York Times notes. 'Just as she varies the difficulty of Wordle puzzles within a week, [Wordle and Strands editor Tracy] FEATURED | Frase ByForbes™ Unscramble The Anagram To Reveal The Phrase Pinpoint By Linkedin Guess The Category Queens By Linkedin Crown Each Region Crossclimb By Linkedin Unlock A Trivia LadderWhat Is Today's Strands Hint? Time to do the NYT hint and then my own hint after that: Breaking up the band And mine is: Two words What Are Today's Strands Answers? Now we begin the answer portion of the program which is the spangram and the full list of the other answers, the spangram is: ROCKGROUPS Here it is on the page, and read on: Strands The answers are: Strands has done this pairs idea before, which means we really only get three answers unless you are positively baffled about the other side. In this case, we have some pretty old rock groups, but not old enough where my millennial self doesn't know them. There are of course a zillion bands that could have qualified for this puzzle, but only so many that fit in the puzzle. Follow me on Twitter, YouTube, and Instagram. Pick up my sci-fi novels the Herokiller series and The Earthborn Trilogy.